novartis glp 1 drug Looming GLP-1 patent expirations draw generics firms GLP-1 use tripled among non-diabetics,

The significant market for diabetes management has fuelled significant innovation in closed-loop delivery systems, but similar technologies are expected to be applied to a range of indications outside of diabetes where self-monitoring and self-administration can bring benefits for patients and payers

Moreover, continued bone metabolism impairment over time in the aftermath of weight loss has been reported in postmenopausal women despite maintaining a stable weight, suggesting a progressive or even delayed effect [7]

This was thought related to the rapid glucose lowering in patients with pre-existing diabetic retinopathy (a known phenomenon where quick improvement of blood sugar can transiently worsen retinopathy)

However, liraglutide use was associated with increased GI symptoms (such as nausea, vomiting

While these studies show the efficacy of these drugs, its still not clear whether the weight lost through GLP-1 drugs consists of fat, muscle or both